作者
Kristen W Cohen, Susanne L Linderman, Zoe Moodie, Julie Czartoski, Lilin Lai, Grace Mantus, Carson Norwood, Lindsay E Nyhoff, Venkata Viswanadh Edara, Katharine Floyd, Stephen C De Rosa, Hasan Ahmed, Rachael Whaley, Shivan N Patel, Brittany Prigmore, Maria P Lemos, Carl W Davis, Sarah Furth, James B O’Keefe, Mohini P Gharpure, Sivaram Gunisetty, Kathy Stephens, Rustom Antia, Veronika I Zarnitsyna, David S Stephens, Srilatha Edupuganti, Nadine Rouphael, Evan J Anderson, Aneesh K Mehta, Jens Wrammert, Mehul S Suthar, Rafi Ahmed, M Juliana McElrath
发表日期
2021/7/20
期刊
Cell Reports Medicine
卷号
2
期号
7
出版商
Elsevier
简介
Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based immune responses. SARS-CoV-2 spike binding and neutralizing antibodies exhibit a bi-phasic decay with an extended half-life of >200 days suggesting the generation of longer-lived plasma cells. SARS-CoV-2 infection also boosts antibody titers to SARS-CoV-1 and common betacoronaviruses. In addition, spike-specific IgG+ memory B cells persist, which bodes well for a rapid antibody response upon virus re-exposure or vaccination. Virus-specific CD4+ and CD8+ T cells are polyfunctional and maintained with an estimated half-life of 200 days. Interestingly, CD4+ T cell responses equally target several SARS-CoV-2 proteins, whereas the CD8+ T cell responses preferentially target the nucleoprotein, highlighting the potential …
学术搜索中的文章
KW Cohen, SL Linderman, Z Moodie, J Czartoski, L Lai… - Cell Reports Medicine, 2021